The US Food and Drug Administration (FDA) has approved lenacapavir, a revolutionary injectable drug that offers six months of continuous protection against HIV infection. This long-acting treatment marks a major breakthrough in expanding prevention strategies, especially for individuals who struggle with taking daily pills.
A Shift from Daily Pills to Biannual Injections
Currently, most HIV prevention methods involve daily oral pills, commonly known as PrEP. However, many people face barriers to adherence—including inconvenience, side effects, social stigma, and cost. Lenacapavir offers an alternative. As a capsid inhibitor, it works by disrupting HIV’s protective shell, preventing the virus from replicating at multiple stages of its lifecycle.
Unlike existing long-acting treatments, lenacapavir is the first and only option to provide protection for a full six months with a single subcutaneous injection.
How Lenacapavir Works
To start treatment, patients take a short course of oral tablets—either for two weeks before or immediately after the injection—to allow the drug to reach protective levels. After that, one injection under the skin every six months keeps the person protected from HIV.
This long-acting format is ideal for people with busy lifestyles, those who forget daily pills, or individuals who prefer more discreet prevention methods. It eliminates the need to carry medication or explain pill use to others, which is especially valuable in high-stigma settings.
Important Caveats and Continued Safe Practices
While lenacapavir is highly effective against HIV, it does not protect against other sexually transmitted infections (STIs). Therefore, continued use of condoms and regular STI screenings remains essential.
As reported by medicalxpress, notably, two breakthrough HIV infections occurred during a pivotal study due to a rare drug-resistant virus mutation. This underscores the need for ongoing medical monitoring to ensure effectiveness and detect resistance early.
Mild Side Effects and Medical Supervision
Most users of lenacapavir do not experience serious side effects. The most common complaint is mild injection-site discomfort, such as redness or swelling, which typically resolves quickly. A small number of individuals reported nausea, but this remains uncommon. Since lenacapavir can interact with other medications, it must be administered under professional medical supervision.
Global Access Hinges on Affordability
Although lenacapavir’s approval in the US is a milestone, its global impact depends heavily on accessibility and price. The drug currently costs approximately US$28,000 per year in the United States. Approval in other regions, such as the UK, is expected in 2025, where the National Institute for Health and Care Excellence (NICE) is already evaluating the drug.
However, the majority of people affected by HIV live in low- and middle-income countries. For lenacapavir to be truly transformative, it must be affordable and widely available. Encouragingly, some researchers believe that generic manufacturers could produce it for as little as US$25 per year if produced at scale. Realizing this potential will require global investment, policy coordination, and health infrastructure support.
Looking Ahead: Once-Yearly Dosing on the Horizon
Gilead, the pharmaceutical company behind lenacapavir, has already presented data on a once-yearly version of the drug, offering even longer protection. If successful, this future development could further simplify HIV prevention and enhance adherence.
Conclusion: A Promising Leap Forward
Lenacapavir represents a major step forward in HIV prevention. With just two injections per year, it provides a simple, discreet, and powerful option for people who cannot—or prefer not to—take daily pills. While it’s not a substitute for condoms or regular testing, it adds a crucial tool to the HIV prevention arsenal.
If scaled globally and made affordable, lenacapavir could significantly advance public health efforts, making HIV prevention more accessible, flexible, and effective for millions around the world.